Complement C3c As a Biomarker in Heart Failure

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2014 Feb 4

PMID 24489446

Citations 17

Authors

A Frey

G Ertl

C E Angermann

U Hofmann

S Stork

S Frantz

Affiliations

Soon will be listed here.

Abstract

Introduction: Experimental data indicates an important role of the innate immune system in cardiac remodeling and heart failure (HF). Complement is a central effector pathway of the innate immune system. Animals lacking parts of the complement system are protected from adverse remodeling. Based on these data, we hypothesized that peripheral complement levels could be a good marker for adverse remodeling and prognosis in patients with HF.

Methods And Results: Since complement activation converges on the complement factor C3, we measured serum C3c, a stable C3-conversion product, in 197 patients with stable systolic HF. Subgroups with normal and elevated C3c levels were compared. C3c levels were elevated in 17% of the cohort. Patients with elevated C3c levels exhibited a trend to better survival, slightly higher LVEF, and lower NTpro-BNP values in comparison to patients with normal C3c values. No differences were found regarding NYHA functional class. Significantly more patients with elevated C3c had preexisting diabetes. The prevalence of CAD, arterial hypertension, and atrial fibrillation was not increased in patients with elevated C3c.

Conclusion: Elevated C3c levels are associated with less adverse remodeling and improved survival in patients with stable systolic heart failure.

Citing Articles

Reward system activation improves recovery from acute myocardial infarction.

Haykin H, Avishai E, Krot M, Ghiringhelli M, Reshef M, Abboud Y Nat Cardiovasc Res. 2024; 3(7):841-856.

PMID: 39196183 DOI: 10.1038/s44161-024-00491-3.

Charting the Proteoform Landscape of Serum Proteins in Individual Donors by High-Resolution Native Mass Spectrometry.

Cramer D, Franc V, Caval T, Heck A Anal Chem. 2022; 94(37):12732-12741.

PMID: 36074704 PMC: 9494300. DOI: 10.1021/acs.analchem.2c02215.

Novel lncRNA-miRNA-mRNA Competing Endogenous RNA Triple Networks Associated Programmed Cell Death in Heart Failure.

Zheng Y, Zhang Y, Zhang X, Dang Y, Cheng Y, Hua W Front Cardiovasc Med. 2021; 8:747449.

PMID: 34692796 PMC: 8528160. DOI: 10.3389/fcvm.2021.747449.

Alternative C3 Complement System: Lipids and Atherosclerosis.

Garcia-Arguinzonis M, Diaz-Riera E, Pena E, Escate R, Juan-Babot O, Mata P Int J Mol Sci. 2021; 22(10).

PMID: 34066088 PMC: 8151937. DOI: 10.3390/ijms22105122.

iTRAQ-based proteomics reveals serum protein changes in hypertensive rats induced by a high-salt diet.

Qin Y, Dong T, Jiang W, Ding W, Zhan T, Du J EXCLI J. 2020; 19:1496-1511.

PMID: 33250683 PMC: 7689244. DOI: 10.17179/excli2020-2740.

References

Frangogiannis N . The immune system and cardiac repair. Pharmacol Res. 2008; 58(2):88-111. PMC: 2642482. DOI: 10.1016/j.phrs.2008.06.007. View

del Balzo U, Levi R, Polley M . Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Natl Acad Sci U S A. 1985; 82(3):886-90. PMC: 397152. DOI: 10.1073/pnas.82.3.886. View

Hofmann U, Frantz S . How can we cure a heart "in flame"? A translational view on inflammation in heart failure. Basic Res Cardiol. 2013; 108(4):356. PMC: 3709073. DOI: 10.1007/s00395-013-0356-y. View

Hill J, Ward P . The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971; 133(4):885-900. PMC: 2138969. DOI: 10.1084/jem.133.4.885. View

Frey A, Kroiss M, Berliner D, Seifert M, Allolio B, Guder G . Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol. 2012; 168(1):300-5. DOI: 10.1016/j.ijcard.2012.09.064. View

Gullestad L, Aass H, Fjeld J, Wikeby L, Andreassen A, Ihlen H . Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001; 103(2):220-5. DOI: 10.1161/01.cir.103.2.220. View

van Diepen S, Roe M, Lopes R, Stebbins A, James S, Newby L . Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis. 2012; 34(1):106-13. DOI: 10.1007/s11239-012-0691-0. View

Kubota T, McTiernan C, FRYE C, Slawson S, Lemster B, Koretsky A . Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997; 81(4):627-35. DOI: 10.1161/01.res.81.4.627. View

Frantz S, Stork S, Michels K, Eigenthaler M, Ertl G, Bauersachs J . Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail. 2008; 10(4):388-95. DOI: 10.1016/j.ejheart.2008.02.015. View

10.

Garred P, Mollnes T, Lea T . Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol. 1988; 27(3):329-35. DOI: 10.1111/j.1365-3083.1988.tb02354.x. View

11.

Schur P, Britton M, Franco A, Corson J, Sosman J, Ruddy S . Rheumatoid synovitis: complement and immune complexes. Rheumatology. 1975; 6:34-42. View

12.

Xia W, Huang Y, Chen Y, Chen S, He J . Acute myocardial ischemia directly modulates the expression of brain natriuretic peptide at the transcriptional and translational levels via inflammatory cytokines. Eur J Pharmacol. 2011; 670(1):7-12. DOI: 10.1016/j.ejphar.2011.09.012. View

13.

Dumestre-Perard C, Ponard D, Drouet C, Leroy V, Zarski J, Dutertre N . Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin Exp Immunol. 2002; 127(1):131-6. PMC: 1906298. DOI: 10.1046/j.1365-2249.2002.01729.x. View

14.

Oksjoki R, Kovanen P, Meri S, Pentikainen M . Function and regulation of the complement system in cardiovascular diseases. Front Biosci. 2007; 12:4696-708. DOI: 10.2741/2419. View

15.

Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6):532-55. DOI: 10.1164/rccm.200703-456SO. View

16.

Aukrust P, Gullestad L, Lappegard K, Ueland T, Aass H, Wikeby L . Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation. 2001; 104(13):1494-500. DOI: 10.1161/hc3801.096353. View

17.

Frantz S, Ertl G, Bauersachs J . Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007; 4(8):444-54. DOI: 10.1038/ncpcardio0938. View

18.

Gallucci S, Matzinger P . Danger signals: SOS to the immune system. Curr Opin Immunol. 2001; 13(1):114-9. DOI: 10.1016/s0952-7915(00)00191-6. View

19.

Fildes J, Shaw S, Yonan N, Williams S . The immune system and chronic heart failure: is the heart in control?. J Am Coll Cardiol. 2009; 53(12):1013-20. DOI: 10.1016/j.jacc.2008.11.046. View

20.

Talasaz A, Khalili H, Jenab Y, Salarifar M, Broumand M, Darabi F . N-Acetylcysteine effects on transforming growth factor-β and tumor necrosis factor-α serum levels as pro-fibrotic and inflammatory biomarkers in patients following ST-segment elevation myocardial infarction. Drugs R D. 2013; 13(3):199-205. PMC: 3784054. DOI: 10.1007/s40268-013-0025-5. View